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Background: With an aging population and an increasing number of elderly patients with cancer, it is essential for
us to understand how cancer physicians approach the management and treatment of elderly cancer patients as
well as their methods of cancer diagnosis disclosure to older versus younger patients in Singapore, where routine
geriatric oncology service is not available.
Methods: 57 cancer physicians who are currently practicing in Singapore participated in a written questionnaire
survey on attitudes towards management of the elderly cancer patient, which included 2 hypothetical clinical
scenarios on treatment choices for a fit elderly patient versus that for a younger patient.
Results: The participants comprised of 68% medical oncologists, 18% radiation oncologists, and 14%
haematologists. Most physicians (53%) listed performance status (PS) as the top single factor affecting their
treatment decision, followed by cancer type (23%) and patient’s decision (11%). The top 5 factors were PS (95%),
co-morbidities (75%), cancer stage (75%), cancer type (75%), patient’s decision (53%), and age (51%). 72% of
physicians were less likely to treat a fit but older patient aggressively; 53% and 79% opted for less intensive
treatments for older patients in two clinical scenarios of lymphoma and early breast cancer, respectively. 37% of
physicians acknowledged that elderly cancer patients were generally under-treated.
Only 9% of physicians chose to disclose cancer diagnosis directly to the older patient compared to 61% of
physicians to a younger patient, citing family preference as the main reason. Most participants (61%) have never
engaged a geriatrician’s help in treatment decisions, although the majority (90%) would welcome the introduction
of a geriatric oncology programme.
Conclusions: Advanced patient age has a significant impact on the cancer physician’s treatment decision-making
process in Singapore. Many physicians still accede to family members’ request and practice non-disclosure of
cancer diagnosis to geriatric patients, which may pose as a hurdle to making an informed decision regarding
management for the geriatric cancer patients. Having a formal geriatric oncology programme in Singapore could
potentially help to optimize the management of geriatric oncology patients.
Keywords: Geriatric oncology, Geriatric oncology service, Cancer disclosure, Cancer treatment, Cancer physicians* Correspondence: soo_chin_lee@nuhs.edu.sg
1Department of Haematology-Oncology, National University Cancer Institute,
National University Health System, Level 7, Tower Block, 1E, Kent Ridge Road,
Singapore 119228, Singapore
3Cancer Science Institute, National University of Singapore, Singapore,
Singapore
Full list of author information is available at the end of the article
© 2013 Pang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Pang et al. BMC Geriatrics 2013, 13:35 Page 2 of 8
http://www.biomedcentral.com/1471-2318/13/35Background
With an ageing population coupled with healthcare
advances, it is expected that an increasing proportion of
patients diagnosed with cancer will be above the age of
65 years worldwide including Asia [1]. Ageing is associ-
ated with an accumulation of medical and social prob-
lems as well as a reduction in physiologic reserves.
These issues need to be taken into account before initi-
ating elderly patients on cancer treatment [2] as they
may face greater treatment related toxicities [3,4].
Singapore is a high-income country within Southeast
Asia with developed healthcare services. While geriatrics
medicine has been an established specialty in Singapore
for 25 years in Singapore, there are as yet no formal
geriatric oncology services in Singapore and no stan-
dardized approach or guidelines in the decision making
process in the treatment of elderly cancer patients.
There are 160 registered cancer specialists in Singapore,
including 80 medical oncologists, 37 radiation oncolo-
gists and 43 haematologists as of 2011. The number of
new cancer patients are on the rise in Singapore, with
11,069 patients diagnosed with cancers in year 2010
compared to 9,417 in 2006 [5]. Patients aged 70 years or
older make up approximately 40% of the cancer patient
load in Singapore, [6] but there are no registered geriat-
ric oncologists in Singapore.
As older patients were often excluded from cancer
clinical trials based on age exclusion criteria [7], the
optimal approach to treatment options for these patients
are often unclear. However, retrospective data and
observational studies have suggested that many older
adults can indeed tolerate and benefit from intensive
cancer treatments, [8-12] and several geriatric assess-
ment scales have been developed to standardize the
decision making process, [13-20] although these scales
are still not routinely used by most cancer physicians in
Singapore.
In Singapore and many Asian countries, most cancer
physicians continue to be deterred by the patients’
advanced age alone and opt for less intensive therapies
which are often also less optimal options [21-23]. A
recent report showed that older Asian breast cancer
patients presented with more advanced disease but were
less likely to receive standard treatment [21]. As cancer
is still largely considered a taboo in Asia with many hav-
ing a fatalistic view towards cancer in Asia, another po-
tential barrier to optimal management is the reluctance
to disclose cancer diagnosis to the elderly patient. Un-
derstanding cancer physicians’ attitudes towards treating
older patients is key to developing strategies to improve
cancer care for these patients. There have been several
surveys with varying sample sizes and survey return
rates conducted in other countries to evaluate this
[24-27] but none to date in Singapore.We devised a questionnaire to survey the cancer physi-
cians in Singapore to identify factors that affect physicians’
decision making process prior to initiating treatment for
older patients. In addition, we investigated cancer physi-
cians’ preferences when dealing with the issue of cancer
diagnosis disclosure to elderly patients, and explored the
level of understanding and acceptance of the introduction
of a multi-disciplinary geriatric oncology team in the man-
agement of elderly cancer patients.
Methods
Participants
The Singapore Medical Council Register of Medical
Practitioners was used to identify cancer physicians in
the respective specialties (medical oncology, radiation
oncology, malignant haematology). In 2011, there were
80 fully registered medical oncologists, 37 radiation on-
cologists and 43 haematologists in Singapore. All cancer
physicians who were actively providing care for cancer
patients were invited to participate in the questionnaire
survey which were distributed to the physicians in
person during combined cancer seminars and collected
back from responding physicians in the same setting.
150 questionnaires were distributed between April to
October 2011. The study protocol was approved by the
local institutional ethics review board. Waiver of written
informed consent was granted as the identity of the
responding physicians was not collected, and return of
completed questionnaire constituted implied consent.
Questionnaire format
We devised our questionnaire survey after reviewing the
relevant literature on similar surveys that have been
conducted amongst cancer physicians [24-27]. The
survey was pilot tested in our institution amongst 10
cancer physicians who had at least 8 years of experience
treating cancer patients to assess the response rates;
feedback was collected with regards to the validity of the
questionnaire. Minor modifications to the survey were
made following the pilot study. The survey (Additional
file 1) consisted of a segment on demographics of the
participants, 11 multiple-choice questions, and 2 clinical
scenarios.
In the 11 multiple choice questions, participants were
asked to rank the most important single factor as well as
the top 5 factors amongst 15 common factors that were
likely to affect the decision making process with regards
to treatment for the elderly oncology patients. The
survey also explored cancer physicians’ perceptions of
the influence of patients’ chronological age on their
treatment choices. In addition, the topic of disclosure of
cancer diagnosis to older patients as compared to youn-
ger patients was evaluated. The level of understanding
and exposure to current geriatric assessment scales and
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into the local practice was explored.
Two case scenarios were used to evaluate the current
practice patterns of cancer physicians in Singapore in
managing elderly patients. In the hypothetical scenarios,
physicians were asked to choose the most appropriate
treatment regimen for an older patient and a younger pa-
tient with the same medical condition. The first case sce-
nario described a fit elderly patient in otherwise good
health who was diagnosed with stage IV diffuse large B
cell non-Hodgkin’s lymphoma (DLBCL). The participants
were asked to choose amongst various curative and pallia-
tive treatment options. The second scenario described a
geriatric patient who had undergone breast lumpectomy
for stage IIB, high risk node positive, hormone receptor
positive, breast cancer. The participants were given treat-
ment options that included adjuvant endocrine therapy
alone and various chemotherapy regimens combined with
endocrine therapy, which would be offered to younger pa-
tients to reduce the risk of disease recurrence and to
improve overall survival. As adjuvant radiation therapy is
the standard of care for women who had undergone
lumpectomy, the participants were also asked if they
would administer radiation therapy to the elderly patient.
Results
Participant demographics (Table 1)
Of the 150 questionnaires distributed to cancer physi-
cians, fifty-seven responded with a return rate of 38%. The
majority were medical oncologists (68%), followed by radi-
ation oncologists (18%) and haematologists (14%). Most
practiced in public hospitals (90%), while 10% were in pri-
vate practice. The majority of the participants were male
(63%). About one-third of the participants had been in
cancer practice for 6 years or more and 70% treated more
than 25 patients per week, typically divided over 2–3 clinic
sessions lasting 3–4 hours each. 77% of participants
reported that geriatric patients older than 65 years made
up more than 30% of their patient population.
Factors influencing physicians’ decision for treatment of
the geriatric oncology patient (Table 2)
The most important single factor that affected physi-
cians’ decision for treatment of a geriatric oncology
patient was performance status (53%), type of cancer
(23%) and patient’s decision (11%). When asked to list the
top 5 factors, the most important factors that emerged
were performance status (95%), co-morbidities (75%),
stage of cancer (75%), type of cancer (75%), patient’s deci-
sion (53%), and age (51%). Of note, slightly more than half
the participants reported age as one of the top 5 factors
that affected their treatment decision, although only 5%
listed it as the most important single reason. Only 19% of
cancer physicians ranked patient’s cognitive function inthe top 5 important factors in determining cancer treat-
ment. The majority (72%) of participants agreed that they
would be less inclined to treat the patients if they were
older. Amongst these participants, 80% reported the age
threshold for less intensive treatment to be 75 years and
above. There was no correlation between physician’s age
(<=40 years versus >40 years) and reluctance to treat an
older patient (77% vs 70%, p = 0.740). A substantial 37% of
the physicians felt that our elderly patient population was
often under-treated, and these physicians indicated the
top 3 reasons to be patient’s preference (81%), family’s
preference (66%) and poor performance status (47%).
Disclosure of cancer diagnosis to patients
With regards to disclosure of cancer diagnosis to older
patients, it was notable that only 9% of participants
Table 2 Factors affecting physicians’ decision for
treatment of geriatric patients
Factor Number of physicians listing
as the most important single
factor
Percentage
Performance status 30 53%
Type of Cancer 13 23%
Patient’s decision 6 11%
Age 3 5%
Factor Number of physicians listing
as one of the top 5 factors
Percentage
Performance status 54 95%
Co-morbidities 43 75%
Type of Cancer 43 75%
Stage of Cancer 43 75%
Patient’s decision 30 53%
Age 29 51%




Age Threshold for treatment (amongst physicians who were less
inclined to treat older patients, n = 41)
65–74 years old 8 20%
75–84 years old 14 34%
85 years old and above 19 46%
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directly, while 54% of physicians chose to disclose the
cancer diagnosis to family members first. When asked to
choose the top 3 reasons for non-disclosure, the reasons
chosen were: the desire to comply with the family’
wishes for non-disclosure to the patient (84%), physi-
cian’s concern about patient’s inability to accept the
diagnosis (55%) and the inability to understand the diag-
nosis (42%). In contrast, more than half the participants
(61%) would disclose the diagnosis of cancer to the
younger patients directly. About one-third of partici-
pants would disclose the cancer diagnosis to the patient
and family members together for both older and younger
patients (37% and 35% respectively). Importantly, none
of the physicians would choose to disclose the diagnosis
to only the elderly patient’s family and not the patient.
Engagement of geriatric specialty services by cancer
physicians
Most participants (61%) have never engaged the help of
a geriatrician in the decision making process for cancer
treatment and only about half the participants (47%)
were aware that there were geriatric oncology assess-
ment scales available. However, the vast majority (90%)
welcomed the introduction of a geriatric oncologyservice, although a proportion (28%) expressed doubts
about its feasibility.
Response to clinical scenarios (Table 3)
In the first clinical scenario involving a fit elderly
patient with stage IV diffuse large B cell non-Hodgkin’s
lymphoma with an International Prognostic Index of 3,
only 47% of participants chose the standard treatment of
6 cycles of R-CHOP or 2 cycles beyond best response
with intrathecal methotrexate. In comparison, 82% of
participants chose the same standard treatment for the
younger patient.
In the second clinical scenario involving an elderly pa-
tient with stage IIB, hormone receptor positive, high risk
node positive breast cancer, only 9% of physicians chose
the option of adjuvant combined chemotherapy and hor-
monal therapy with 4 cycles of doxorubicin/cyclophospha-
mide, followed by weekly paclitaxel and an aromatase
inhibitor for 5 years, which was the most aggressive treat-
ment option. Almost 80% physicians chose only adjuvant
endocrine therapy with an aromatase inhibitor (64%) or
tamoxifen (15%) for 5 years without adjuvant chemother-
apy. In contrast, if the patient was younger, at least 96% of
participants would treat the patient with combined adju-
vant chemotherapy and endocrine therapy and none
would treat the patient with adjuvant endocrine therapy
alone. Slightly more than two-thirds (68%) of participants
would treat the elderly patient with adjuvant radiation
therapy after lumpectomy surgery.
In both scenarios, physicians were asked to choose the 3
top factors that affected their decision for treatment. For
scenario 1, most physicians chose performance status
(85%), cancer type (67%) and cancer stage (36%) as the
top 3 factors, while for scenario 2, the top 3 factors were
cancer stage (72%), cancer type (60%) and performance
status (47%).
Discussion
Treatment of geriatric patients (>65 years old) with can-
cers can be challenging due to multiple medical, physio-
logical, social as well as economic factors. In multi-ethnic
Singapore, further challenges may arise from cultural dif-
ferences, as well as the family’s involvement in disclosure
of cancer diagnosis and formulation of treatment options.
In this study, physicians ranked age as only the sixth
most important factor affecting their treatment decision
for cancer patients, with only 5% of participants ranking
it as the most important factor. The top factors chosen
by the physicians were instead, performance status, co-
morbidities, patient’s decision, cancer type and stage.
Age was similarly not cited as one of the top three
factors affecting treatment decisions in the two clinical
scenarios. Yet, a striking discrepancy was observed in
the actual treatment choices in the clinical scenarios,
Table 3 Response to clinical scenarios
Scenario 1: Stage IV Diffuse Large B-cell Non-Hodgkin’s Lymphoma (n = 55)
Treatment options for the older patient Number Percentage
R-CHOP1 × 6 + Intrathecal Methotrexate 26 47%
R-CVP2 × 6 21 38%
CHOP3 × 6 4 7%
Palliative radiotherapy 3 6%
Best Supportive Care 1 2%
Treatment options for the younger patient Number Percentage
RCHOP × 6 + Intrathecal Methotrexate 45 82%
R-CVP × 6 7 13%
CHOP × 6 3 5%
Palliative radiotherapy 0 0%
Best Supportive Care 0 0%
Factors affecting treatment decision
Performance Status 47 85%
Cancer type 37 67%
Cancer stage 20 36%
Patient decision 16 29%
Co-morbidities 15 27%
Age 14 25%
Scenario 2: Stage IIB, Node positive, Hormone receptor positive Breast cancer (n = 53)
Treatment options for the older patient Number Percentage
Aromatase inhibitor × 5 years 34 64%
Tamoxifen × 5 years 8 15%
AC4 × 4→ T5 × 12, then endocrine treatment 5 9%
CMF6 × 6, then endocrine treatment 1 2%
FAC7 × 6, then endocrine treatment 1 2%
Others 4 8%
Treatment options for younger patient Number Percentage
AC × 4→ T × 12, then endocrine treatment 44 83%
FAC × 6, then endocrine treatment 5 9%
CMF × 6, then endocrine treatment 2 4%
Others 2 4%
Aromatase inhibitor × 5 years 0 0%
Tamoxifen × 5 years 0 0%
Factors affecting treatment decision Number Percentage
Cancer Stage 38 72%
Cancer Type 32 60%
Performance Status 25 47%
Age 24 45%
Patient decision 16 30%
Co-morbidities 9 17%
1R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone; 2R-CVP: Rituximab, Cyclophosphamide, Vincristine and Prednisolone;
3CHOP: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone; 4 AC: Doxorubicin and Cyclophosphamide; 5 T: Paclitaxel; 6CMF: Cyclophosphamide,
Methotrexate and 5 Fluorouracil; 7FAC: 5 Flurouracil, Doxorubicin and Cyclophosphamide.
Two and four surveys each were incomplete for scenario 1 and scenario 2. Four participants who were haematologists were not familiar with treatment of breast
cancer and opted not to fill in the section of the survey pertaining to the case scenario for breast cancer. Similarly, two oncologists opted not to fill in the
lymphoma case scenario as they had limited experience treating patients with lymphoma.
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for the older compared to the younger patient. The
majority of the physicians also admitted that they were
less inclined to treat patients more than 75 years old.
These findings underscore the fact that advanced
chronological age alone still deters most physicians from
offering geriatric patients standard-of-care treatments in
real life.
The geriatric population is a heterogeneous one with
varying functional reserves and life expectancies. Par-
ticularly in this population, preserving functional status
is as important an outcome as cancer-free survival. Anti-
cancer treatments that are proposed must be in line with
each patient’s life expectancy and performance status so
that the patient is able to tolerate the side effects of the
prescribed therapy and live long enough to derive actual
efficacy benefits. Comprehensive geriatric assessment
serves to define an initial level of performance, and
yields information that may help guide physician deci-
sion about treatment after taking into account projected
life-expectancy and potential tolerance to side-effects.
Hence, a more structured approach is desirable to
optimize treatment options for geriatric patients. Geriat-
ric assessment scales have been developed to standardize
and facilitate the decision making process with the help
of a multi-disciplinary team, [13-15] and various studies
have been done to evaluate the feasibility and practical
application of these assessment scales in the healthcare
setting [16-20]. For example, a study done in Singapore
[16] looked at the incorporation of a Comprehensive
Geriatric Assessment (CGA) scale in the management of
Asian elderly cancer patients, and identified age, poor
performance status, abnormal albumin level, abnormal
geriatric depression scale, high malnutrition risk and
advanced disease stage as independent predictors of over-
all survival. The integration of these assessment scales into
routine oncology care may help to optimize care.
One potential barrier to managing an elderly cancer
patient in Asia is the reluctance to disclose cancer diag-
nosis to the patient by family members. Singapore is a
multi-ethnic country comprising of three major Asian
ethnic groups, Chinese, Malay and Indian, that have dif-
ferent mother tongues, religious beliefs and cultural
practices. In such a setting, the management of geriatric
patients may pose an even greater challenge especially
during communication. Amongst the Singaporean geri-
atric population, the majority (80%) have below second-
ary educational qualifications, and many spoke only
their mother tongue (Chinese dialects, Malay, or Tamil)
which the treating physician may not be fluent at,
instead of the official language, English. As in most
Asian countries, a large proportion (86%) stay with their
spouse or children and the main source of financial
support come from their children (63%) [28]. Thesesocial circumstances account for the important role the
family plays during the decision making process for the
treatment of elderly cancer patients.
Less than 10% of cancer physicians in this study chose
to disclose cancer diagnosis to the older patients dir-
ectly, in contrast to the preference of disclosing the news
directly to the younger patient, though none of the phy-
sicians will opt to keep the diagnosis from the patients
entirely. This is in contrast to the West, where disclos-
ure of cancer diagnosis to the patient has been the norm
for more than three decades [29-32]. A study by Novack
et al. [29] in 1971 reported that 97% of physicians will
disclose the truth to the cancer patients. In contrast,
Kawakami et al. [33] showed that even with decisional
ability, 15% of cancer patients in Japan were not told
their cancer diagnosis as the wishes of their family
governed whether disclosure occurred, although another
Japanese study by Matsumura et al. in 1997 [34] showed
that the majority of patients with cancer wished to know
their diagnosis, regardless of the cancer stage. Some phy-
sicians may argue that withholding the diagnosis from
elderly patients who do not wish to be told is a compas-
sionate option that respects the patient’s wishes. Inter-
estingly, two recent studies [35,36] showed that in
patients with advanced cancer, there was in fact better
emotional and quality of life with lack of awareness in
patients. However, for patients who wish to know, it will
be unethical to withhold the diagnosis. Some physicians
attempt to reach a compromise by breaking the news in
a sequential fashion to the patient and family, which
allows for mutual emotional support and a combined
discussion to facilitate decision making about treatment.
This could be a feasible option in our cultural settings
and was indeed the preferred option by one-third of the
physicians we surveyed.
More than half of the participants in our study have
never engaged the help of a geriatrician and half of them
were not aware of the availability of geriatric assessment
scales. 28% of the physicians were also concerned about
the feasibility of establishing a geriatric oncology pro-
gram in Singapore mainly due to the lack of geriatricians
in Singapore. Reassuringly, the vast majority was recep-
tive to the establishment of a formal geriatric oncology
program. This may start with the integration of a struc-
tured geriatric assessment scale in routine oncology care.
The current limitations of setting up a geriatric oncology
program include the paucity of trained specialists such
as geriatric oncologists and allied health staff. Neverthe-
less, these are changes that should be implemented with
time in order to facilitate the management of the ageing
population with cancer.
There are some limitations to this study. Firstly, the
number of physicians who participated in the survey was
less than half of the targeted population. Secondly, many
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about a third of our participants having 6 years or more
of clinical experience, although the majority had
adequate exposure to cancer patients of the geriatric age
group. Thirdly, our target cancer physician population
included haematologists and medical oncologists some
of whom were not familiar with the treatment of breast
cancer and lymphoma patients respectively, resulting in
incomplete responses to the two clinical scenarios.Conclusion
In Singapore, advanced age influenced treatment decisions
among many cancer physicians, who are still inclined to
treat an elderly cancer patient less intensively. Few cancer
physicians were aware of formal geriatric assessment
scales, and few have engaged the help of a geriatrician in
the cancer treatment decision making process. However,
most physicians were positive that a geriatric oncology
program could benefit patients, and additional study to
understand the attitudes of our geriatricians will be helpful
as they will play an essential role in the development of a
geriatric oncology program in Singapore. The practice of
non-disclosure of cancer diagnosis is a potential barrier to
the optimal management of geriatric patients, although in
our cultural setting, disclosing the diagnosis to both the
patient and family together or in a sequential manner
could be a feasible compromise. The incorporation of
assessment scales and management guidelines followed by
establishment of a formal geriatric oncology program can
potentially optimize the care of the elderly cancer patient
in Singapore.Additional file
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